LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the Savara Early Access ...

Program Enables Physicians to Request Molgramostim for Eligible Patients in Select Geographies Where the Product is Not Commercially Available and in Compliance with Local Regulatory Requirements ...

LANGHORNE, Pa. - Savara Inc. (NASDAQ:SVRA), a biopharmaceutical company specializing in rare respiratory diseases, announced the initiation of an Expanded Access Program (EAP) for molgramostim, ...

AUSTIN, Texas--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the response from a Type C meeting with the U.S. Food and Drug Administration (FDA) ...

Plus, get the best of BroadwayWorld delivered to your inbox, and unlimited access to our editorial content across the globe. The Association of Performing Arts Professionals announced the nominees for ...

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the response from a Type C meeting with the U.S. Food and Drug Administration (FDA) ...

Unlock access to every one of the hundreds of articles published daily on BroadwayWorld by logging in with one click. The Association of Performing Arts Professionals announced the nominees for its ...

Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the response from a Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the Molgradex development ...